Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advised Nextmune in connection with its acquisition of I.C.F. S.r.l and D.R.N. S.r.l.
Mandate

Vinge advised Nextmune in connection with its acquisition of I.C.F. S.r.l and D.R.N. S.r.l.

October 08, 2020 Banking and Finance M&A

Vinge has advised Fidelio Capital and its portfolio company Nextmune, a leading science driven, global specialty pharmaceutical company dedicated to improving health for dogs, cats and horses, in connection with its acquisition of I.C.F. S.r.l and D.R.N. S.r.l.

Vinge’s team consisted of, among others, Jonas Bergström, Matthias Pannier, Maria Dahlin-Kolvik, Karl Klackenberg, Manne Bergström, Vilhelm Rondahl and Albert Wållgren, Josefine Lanker, Axel Jansson och Jolinn Uhlin.

Related

Vinge has advised Verisure in connection with its IPO on Nasdaq Stockholm

 Vinge has advised Verisure plc (“Verisure”) in connection with its IPO on Nasdaq Stockholm. Following the publication of the prospectus on 29 September 2025, trading in Verisure’s shares commenced today, 8 October 2025.
October 08, 2025

Vinge has acted for Advania on the acquisition of smartvokat

smartvokat GmbH, a German-based consultancy specialising in digital transformation within the legal, risk, and compliance domains, will become part of Advania’s business unit Transformation & Automation.
October 08, 2025

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025